NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Centessa Pharmaceuticals' financial results for Q4 2021 were reported, along with a business update that highlights a strengthened strategic focus on rare disease and immuno-oncology assets.
Centessa Pharmaceuticals reported cash and cash equivalents of $595.1 million as of December 31, 2021. The company is focusing on rare disease and immuno-oncology assets, with SerpinPC registration studies planned for 2H 2022 and LB101 preclinical data expected at ASCO 2022.
- Strategic focus strengthened on rare disease and immuno-oncology assets.
- SerpinPC registration studies are planned to begin in the second half of 2022, focusing on Hemophilia B.
- LB101 preclinical data is expected to be shared at ASCO 2022, with an IND planned for late 2022.
- Cash and cash equivalents totaled $595.1 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Centessa Pharmaceuticals is advancing multiple programs towards key milestones, including registrational studies for Lixivaptan and SerpinPC, and IND filings for LB101, LB201, MGX292, CBS004 and OX2R Agonists.
Tailwinds
- Lixivaptan is currently being administered in the Phase 3 registrational ACTION Study.
- SerpinPC: In the second half of 2022 the Company expects to launch two registrational studies.
- LB101 preclinical data is expected to be shared at ASCO 2022, with an IND for LB101 planned for late 2022.
- ZF874: We expect to share Phase 1 data from multiple dose cohorts with PiMZ and PiZZ subjects in 2H 2022.
- CBS001 in Inflammatory / Fibrotic Diseases: Phase 1 clinical trial in healthy volunteers is expected to begin in the second quarter of 2022.
Headwinds
- Discontinued the small molecule EGFR inhibitor discovery program.
- Evaluating strategic options for imgatuzumab.
- Discontinued internal funding for the lead dual-STAT3/5 degrader program.
- The ACTION Study is expected to enroll ~1,350 subjects across>200 sites in over 20 countries, with completion anticipated in the second half of 2023.
- Registrational plans for Hemophilia A are in development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro